Compare VELO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | VRCA |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 87.5M |
| IPO Year | N/A | 2018 |
| Metric | VELO | VRCA |
|---|---|---|
| Price | $9.99 | $4.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $17.00 |
| AVG Volume (30 Days) | ★ 1.8M | 117.9K |
| Earning Date | 03-24-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $38.71 | $92.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $2.87 | $0.39 |
| 52 Week High | $23.84 | $9.82 |
| Indicator | VELO | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 32.23 |
| Support Level | $3.41 | $3.96 |
| Resistance Level | $15.92 | $4.87 |
| Average True Range (ATR) | 1.62 | 0.59 |
| MACD | -0.29 | -0.12 |
| Stochastic Oscillator | 3.05 | 10.58 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.